Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of...

12/04/2018 - 01:30

ASPIRE and B-YOND extension studies show no inhibitor development and consistently low annualised bleeding rates in study participants over four years with Elocta and Alprolix, respectively.

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Bioverativ Inc., a Sanofi...

12/01/2018 - 17:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are pleased to announce that the abstract “Safety and efficacy of emapalumab in paediatric patients with primary hemophagocytic lymphohistiocytosis” was accepted as a late-breaking abstract at the 60th Annual...

11/22/2018 - 13:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI), an international biopharmaceutical company dedicated to rare diseases, and Novimmune SA, a Swiss biotech company, today announce that the US Food and Drug Administration (FDA) has approved Gamifant® (emapalumab...

11/20/2018 - 15:29

Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Paula Treutiger as Head of Communications and Investor Relations. Paula will join Sobi on 1 January 2019 and be part of Sobi’s Executive Committee.

Paula joins Sobi from Medicover, an international healthcare and...

11/19/2018 - 09:00

Press contacts

Subscribe to our press releases and financial reports